Deal Analysis
Nov 19, 2026

Kardi AI's €5.3M Series A Is Smaller Than Three in Four European Health Tech Rounds

2020 to November 2026

€5.3M
Series A, led by Callisto Health
76%
European health tech Series A rounds since 2025 that were larger
€10.0M
Median European health tech Series A
19
Months from the 2025 round (European median 27)
CZK 600M
Reported valuation after the round
1 of 8
Comparable companies acquired
  • Kardi AI raised a €5.3M (CZK 130M) Series A led by Callisto Health, with four earlier backers investing again.
  • The round is smaller than 76% of European health tech and medtech Series A rounds since 2025, about half the €10.0M median. It is a Czech medtech record but not a regional one: Slovak Powerful Medical has raised over €53M, mostly EU money.
  • Kardi AI sells certified software on a third-party ECG strap. All eight European diagnostic software peers with a Series A since 2024 raised more (median €12.5M), and so did eight earlier ECG startups, one of them bought by Philips.
  • The Czech company booked CZK 3.8M of 2025 revenue against a reported CZK 600M valuation, and CZK 40.4M of investor money still waits to become shares.

Kardi AI, a medical technology startup from Olomouc, raised a Series A of €5.3 million (CZK 130 million) on 11 November 2026. Callisto Health, a German health tech fund, led it. The Seed Starter programmes of Česká spořitelna and Slovenská sporiteľňa joined, and four earlier backers put in more: BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels. Kardi AI sells software, certified as a class IIa medical device according to the company, that reads ECGs from a Polar H10 chest strap and flags heart rhythm disorders. The strap is made by Polar; Kardi AI ships it with the service and does not sell a licence without it. The company says the software does not make the diagnosis; doctors do. More than 70 Czech hospitals and 20 employers and benefit providers use it, with over 6,000 users. The money goes to Germany first, then India, the UAE and Singapore, and to models that estimate a patient's risk of arrhythmia before it shows up.

The problem: a small Series A

Brouky has 131 Series A rounds with an amount since January 2025 from European health tech and medical device startups, leaving out biotech and drug developers. Kardi AI's €5.3 million is smaller than 76% of them: 99 of the 131 raised more. The median is €10.0 million, almost twice Kardi AI's round. A top quarter round starts at €15.6 million.

Series A size, European health tech and medtech

Rounds since January 2025, € million. The bottom 25% raised up to €5.7M, the top 10% from €30.4M

Share chart

Kardi AI does not build hardware, so it does not need device-sized money for manufacturing and stock. It is not pure software either. The service works only with the strap it ships, so in every new market Kardi AI has to buy, ship and support that hardware through its hospital and employer channels. Its closest peers are European diagnostic software companies: AI that reads ECGs, scans or slides recorded on someone else's equipment. We found eight of them with a Series A announced since 2024 with an amount, and read each round at the source.

European diagnostic software Series A rounds, 2024 to 2026

Software that reads data from other makers' equipment, each round checked at the source, € million

Share chart

All eight raised more than Kardi AI. The median was €12.5 million, more than twice Kardi AI's round, and the smallest, Qureight's, was €7.8 million. CardioSignal, the only other one that reads a consumer sensor (a phone's motion sensors), raised €9.2 million in January 2024. Being software did not make these rounds smaller than the wider health tech median of €10.0 million.

Largest in Czechia, not in the region

Kardi AI says this is the largest round a Czech medtech startup has raised, and Forbes Czech Republic calls it a record. Our data agrees for Czechia: only biotech and cell manufacturing companies such as SOTIO and SCTbio have raised more in a single Czech healthcare round.

Across Central and Eastern Europe the claim does not hold. Powerful Medical in Bratislava, which also reads ECGs with AI, raised a €6.2 million seed in 2022, already more than Kardi AI's Series A. In February 2024 the European Innovation Council added €7.5 million: a €2.5 million grant and €5 million of equity. In July 2025 it won a non-dilutive EU grant of over €40 million through the IPCEI Tech4cure programme. That is over €53 million in total, and about 88% of it is public money. Powerful Medical has said since 2024 that it is raising a $25 million Series A; no close has been announced. Elsewhere in the region, Mediately (Slovenia) raised a €7.2 million Series A in 2022 and Jutro Medical (Poland) a €12 million Series A in 2025, extended by €24 million.

Fast, but small

The round came faster than usual. Kardi AI raised €1.1 million in April 2025, 19 months before this Series A. For the 28 European health tech companies in our set with a dated seed, the median gap from seed to Series A was 27 months. About a third moved as fast. Counted from its €1.5 million seed of November 2023, Kardi AI took 36 months.

Months from seed to Series A

European health tech and medtech Series A rounds since January 2025

Share chart

What the price says

Czech press reported a valuation of CZK 600 million after the round, about €23 million. On those two figures the new money buys roughly a fifth of the company. In 2025 the Czech company booked revenue of CZK 3.8 million, up 51% on the year before, and a loss of CZK 20.7 million. The valuation is about 158 times that revenue. Investors are paying for the hospital network, the certified software and the expansion plan, and for a predictive product that still needs expert validation and regulatory approval.

What happened to companies like Kardi AI

We took eight startups that analyse ECGs or monitor heart rhythm and raised a Series A between 2020 and 2024, and checked each one against the press. Every one of those Series A rounds was larger than Kardi AI's. The smallest, PaceMate's, was $8 million.

Heart rhythm and ECG startups with a Series A in 2020 to 2024
CompanyHQSeries A, as announcedWhat happened next
CardiologsFrance$15M, Jan 2020, AlvenBought by Philips, Nov 2021
PaceMateUnited States$8M, Mar 2021, Ballast PointLead Edge invested, Jul 2023, terms undisclosed
AnumanaUnited StatesAbout $26M, 2021, nference and Mayo Clinic$95.4M Series C, Apr 2025
ImplicityFrance€21M, 2022, Crédit Mutuel Innovation and Bpifrance€35M growth round led by IRIS, Sep 2026
IdovenSpain$12.9M, Jun 2022, Insight Partners and NorthzoneFollow-on with the same funds, 2023, undisclosed
CardiosenseUnited States$15.1M, Dec 2022, Broadview and HatterasUS filing shows $26.1M sold, Aug 2026
CardioSignalFinland$10M, Jan 2024, DigiTx PartnersNo later round found
Vektor MedicalUnited States$16M, Feb 2024, Solas and TVMNo later round found

What happened to 8 comparable companies

ECG and heart rhythm startups with a Series A in 2020 to 2024

Share chart

Philips bought Cardiologs 22 months after its Series A, the one exit in the group. Anumana and Implicity went on to raise much larger rounds, Implicity more than four years after its Series A. PaceMate, Idoven and Cardiosense raised again on terms they did not announce. CardioSignal and Vektor Medical have no later round on record. None has shut down.

Our read. The problem is the size. Kardi AI raised less than three in four European health tech Series A rounds, less than every European diagnostic software company with a Series A since 2024 that we checked, less than every ECG company in this group, and less than its Slovak neighbour got in grants. It is a record for Czech medtech and a small round for Europe. The company has the hospital network and software that reads a third-party sensor, close to Cardiologs, the one company here that a buyer took. In this group the next deal came one to four years after the Series A. With €5.3 million, Kardi AI has to show German sales well before then.

The Czech company behind it

Kardi AI trades as KARDI AI Technologies s.r.o. (IČO 14328127), registered in Olomouc on 10 March 2022 by Stephen Burke, cardiologist Tomáš Skála, David Skála and Pavel Digaňa with CZK 500,000 of share capital. The November 2023 seed raised it to CZK 1.1 million and brought in BrightCap, DEPO, Purple Ventures, Soulmates Ventures, Cleverage and two Czech holding companies. The four founders still hold 61% of the registered shares. Vlastimil Hrabal, who became CEO later, holds a power of attorney (prokura) since October 2023.

The register has not caught up with the money since. At the end of 2025 the company held CZK 40.4 million as long-term advances received: investor money that has not yet turned into shares. That left equity at minus CZK 13.9 million on paper, with CZK 15.3 million in the bank. The new shares from the 2025 round and the Series A should show in the register once they are issued.

Mar 2022Company registered, BrightCap pre-seed
Nov 2023€1.5M seed
Apr 2025€1.1M third round
Nov 2026€5.3M Series A, Callisto Health leads
NextGermany, then India, UAE, Singapore

Investors in the round on Brouky: Callisto Health, Seed Starter ČS, Seed Starter SK, BrightCap Ventures, Purple Ventures, DEPO Ventures, Garage Angels.

Sources

Series A: tech.eu, Lupa.cz and The Recursive, 11 November 2026. Earlier rounds: AIN, November 2023; tech.eu and CzechCrunch, April 2025. Czech commercial register, KARDI AI Technologies s.r.o., and its collection of deeds (accounts for 2023 to 2025).

Comparable companies: Cardiologs (Series A, Philips), PaceMate (Series A, 2023), Anumana (Series A, Series C), Implicity (Series A, 2026), Idoven (Series A, 2023), Cardiosense (Series A, filing), CardioSignal (Series A), Vektor Medical (Series A). Brouky investment data, 2020 to November 2026.

Kardi AI product: Kardi AI store and user manual. Diagnostic software Series A rounds: Quibim, Cerebriu, AZmed, Mindpeak, BrightHeart, Lucida Medical, CardioSignal, Qureight.

Region: Powerful Medical (seed, EIC, IPCEI grant, Series A plan), Mediately, Jutro Medical (Series A, extension), Forbes Czech Republic.

Share this article

Related insights

Explore the full dataset

Brouky tracks 37,000+ investors and 122,000+ investments across 134,000+ startups. Search by country, stage, and sector.